Currently, there are 63.77M common shares owned by the public and among those 48.07M shares have been available to trade.
The company’s stock has a 5-day price change of 19.79% and -21.24% over the past three months. VERA shares are trading -46.32% year to date (YTD), with the 12-month market performance down to -42.49% lower. It has a 12-month low price of $18.53 and touched a high of $51.61 over the same period. VERA has an average intraday trading volume of 1.37 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.49%, -0.20%, and -34.97% respectively.
Institutional ownership of Vera Therapeutics Inc (NASDAQ: VERA) shares accounts for 90.09% of the company’s 63.77M shares outstanding.
It has a market capitalization of $1.45B and a beta (3y monthly) value of 1.11. The earnings-per-share (ttm) stands at -$3.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.77% over the week and 14.01% over the month.
Analysts forecast that Vera Therapeutics Inc (VERA) will achieve an EPS of -0.63 for the current quarter, -0.83 for the next quarter and -2.98 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.9 while analysts give the company a high EPS estimate of -0.9. Comparatively, EPS for the current quarter was -0.62 a year ago. Earnings per share for the fiscal year are expected to decrease by -20.32%, and -4.12% over the next financial year. EPS should grow at an annualized rate of 12.94% over the next five years, compared to 4.49% over the past 5-year period.
Looking at the support for the VERA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on May 05, 2025, with the firm’s price target at $75. Wolfe Research coverage for the Vera Therapeutics Inc (VERA) stock in a research note released on February 04, 2025 offered a Outperform rating with a price target of $49. Goldman was of a view on January 28, 2025 that the stock is Buy, while Wells Fargo gave the stock Overweight rating on November 21, 2024, issuing a price target of $70. Scotiabank on their part issued Sector Outperform rating on October 16, 2024.
